The cost effectiveness of pharmacotherapies for smoking cessation: necessary but not sufficient?
Shanahan
Marian
M
National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Sydney, Australia.
Doran
Christopher
C
Gates
Jennifer
J
Shakeshaft
Anthony
A
Mattick
Richard P
RP
D000279:Administration, Cutaneous; D001315:Australia / Q000453:epidemiology; D016642:Bupropion / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D003657:Decision Making; D016527:Drug Costs / Q000706:statistics & numerical data; D006301:Health Services Needs and Demand / Q000191:economics; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage* / Q000191:economics; D010342:Patient Acceptance of Health Care; D012907:Smoking / Q000188:drug therapy* / Q000453:epidemiology; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods; D016896:Treatment Outcome
D016642:Bupropion; D009538:Nicotine